CD4 and myocardial infarction: In this study, we provide novel evidence that pre-transplantation systemic intravenous administration of hiPSC-MSCs can induce immunomodulatory effects through activation of Tregs, suppression of NK cells, and modulation of the expression of cytokine profiling of CD4+ cells to enhance engraftment and survival of cells transplanted intramyocardially for treatment of MI.